RecruitingNot ApplicableNCT07206602
AI-Guided Left Bundle Branch Area Pacing
A Pilot Study Assessing Outcomes Of Artificial Intelligence-Guided Left Bundle Branch Area Pacing For Cardiac Resynchronization In Heart Failure
Sponsor
Mayo Clinic
Enrollment
224 participants
Start Date
Jan 23, 2026
Study Type
INTERVENTIONAL
Conditions
Summary
The purpose of this study is to compare the effectiveness of AI-guided LBBAP versus conventional LBBAP (not AI-guided) in improving CRT response rates and clinical outcomes.
Eligibility
Min Age: 18 Years
Inclusion Criteria5
- Age: 18 years or older.
- Left Ventricular Ejection Fraction (LVEF): \<50% within 6 months prior to enrollment.
- QRS Duration: Resting QRS duration ≥ 130 ms on ECG OR anticipated right ventricular pacing \> 40% OR device in place with right ventricular pacing \> 40% within 6 months prior to enrollment.
- Medical Therapy: Optimized on guideline-directed medical therapy for heart failure.
- AI-ECG probability of low LVEF: \>0.5
Exclusion Criteria3
- Age less than 18 years old
- Inability to follow-up
- Pregnancy
Interventions
DEVICEAI-assisted Left Bundle Branch Area Pacing
Patients will undergo a Left Bundle Branch Area Pacing (LBBAP) procedure using AI assisted technology
PROCEDURELeft Bundle Branch Area Pacing
Patients will undergo a Left Bundle Branch Area Pacing (LBBAP) procedure
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07206602
Related Trials
Mind Your Heart-II
NCT054311921 location
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
NCT06424288652 locations
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
NCT06935370641 locations
Timing of Coronary Angiography in NSTEMI Complicated by Acute HF
NCT0700216420 locations
ML Score Prediction of Cardiotoxicity in Cancer Patients Receiving Anthracycline Chemotherapy or HER2-Targeted Therapies
NCT071917301 location